Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
'Pluribus' release date: Everything you need to know about the new series from 'Better Call Saul's' co-creator - 2Rocket Lab launches mystery satellite for 'confidential commercial customer' (video)
- 3Hamas demanded displaced Gazans pay rent on beach tents amid torrential downpour, IDF reveals
- 4They grew up with 'almond moms.' Now, they dread going home for the holidays.
- 5Is 'Veronica Mars' about to be your new binge-watch? It's now streaming on Netflix.
- Artemis 2 astronauts arrive at Kennedy Space Center ahead of NASA's historic launch around the moon
- Audits of 6 Specialty Mixed drinks
- Congress is running out of time to extend ACA subsidies as the GOP moves on to an alternative plan. Here's where things stand.
- UN rights chief: Israel's new Gaza aid agency rules 'outrageous'
- Step by step instructions to Open a Lovely Waterway Voyage Insight: Conveniences, Administrations, and Elite Offers
- 2025 Was Another Exceptionally Hot Year
- Pick Your Favored method of transportation
- Smartwatches: Remain Associated and Dynamic
- UN warns civil liberties under threat due to war in Middle East
